SRAMF (Sisram Medical) Risk Assessment


SRAMF Sisram Medical Ltd SRAMF
49 GF Score
Price $0.44
GF Value $0.98
Valuation Significantly Undervalued
! 5 Warning Signs
View Full Analysis

What is Sisram Medical Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Sisram Medical is: Low Risk: Strong fundamentals, worth long-term holding.

Sisram Medical  (OTCPK:SRAMF) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Sisram Medical Risk Assessment Related Terms

SRAMF vs ABT, SYK, MDT: Risk Assessment Comparison

For the Medical Devices subindustry, Sisram Medical's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sisram Medical Risk Assessment vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Sisram Medical's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Sisram Medical's Risk Assessment falls into.


SRAMF
49GF Score
Sisram Medical Ltd SRAMF
Risk Assessment is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Sisram Medical (SRAMF) Overvalued in 2026?

Based on GuruFocus' analysis, Sisram Medical stock appears to be undervalued. The current stock price of $0.44 is trading 55.3% below its estimated GF Value™ of $0.98. GuruFocus considers Sisram Medical to be Significantly Undervalued.

Key valuation signals for SRAMF:

  • Risk Assessment:
  • GF Value™: $0.98 vs. price of $0.44 (55.3% below fair value)
  • GF Score™: 49/100 with 5 warning signs

No single metric tells the full story. See the SRAMF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sisram Medical Business Description

Other Exchanges 01696:Hong Kong
Address HaHarash Street 18, Ofek Building 15, Industrial Park, Caesarea, ISR, 3079895
Sisram Medical Ltd is an investment holding company specializing in medical technology for healthcare. The Company is involved in research, development, design, manufacture, sale and marketing of medical aesthetics and dental equipment, home use devices, injectables and cosmeceuticals products. The company's products include Soprano Titanium, Colibri technology, and others. Some of the company's brands are Alma, Soprano, Copulla, and LMNT. It operates through the following geographical segments: North America which is its key revenue generating market, Europe, Asia Pacific, Latin America, and the Middle East and Africa.
49GF Score

Get the complete analysis for SRAMF

Risk Assessment is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.44
Price
$0.98
GF Value